Ductal adenocarcimoma of the prostate is “rare” but aggressive

Pure ductal adenocarcinoma of the prostate (dPC) is thought to be found in just 0.4 to 0.8 percent of men who get diagnosed with prostate cancer each year. … READ MORE …

Advances in the identification of patients who may respond well to particular types of immunotherapy

A newly published paper by an international group of investigators has given us some further insight in to the roles of immunotherapeutic agents in the treatment of at least a subset of men with advanced forms of prostate cancer. … READ MORE …

Prevalence of DNA-repair germline mutations in men with metastatic prostate cancer

A new study in this week’s New England Journal of Medicine reports that DNA-repair germline mutations were found in nearly 12 percent of patients who had metastatic prostate cancer. … READ MORE …

The accurate assessment of risk profiles among high-risk prostate cancer patients

A key question in management of prostate cancer is the risk that a particular patient has disease — at the time of diagnosis — that will progress over time to become metastatic. The ability to answer this question with accuracy is fundamental to the need for aggressive, early treatment. … READ MORE …

“Lynchpin molecule for the spread of cancer found”

This type of heading in media stories and press releases tends to drive your Sitemaster to distraction because there is almost invariably a major “may” or a “possibly” in the actual story when you get into the details. However, in this particular case there may be some justification for the headline. … READ MORE …